By Amina Niasse and Kunal Das Nov 9 (Reuters) – Hims & Hers Health said on Monday it will begin offering some unapproved peptide treatments in November after US regulators eased curbs, with plans to
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)